Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies ↗

August 22, 2023

Via Benzinga

Analyst Expectations for Intra-Cellular Therapies's Future ↗

August 03, 2023

Via Benzinga

Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data ↗

July 06, 2023

Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are...

Via Benzinga

Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know ↗

July 06, 2023

Via Benzinga

Analyst Expectations for Intra-Cellular Therapies's Future ↗

June 22, 2023

Via Benzinga

Analyst Expectations for Intra-Cellular Therapies's Future ↗

June 05, 2023

Via Benzinga

Recap: Intra-Cellular Therapies Q1 Earnings ↗

May 04, 2023

Via Benzinga

A Preview Of Intra-Cellular Therapies's Earnings ↗

May 03, 2023

Via Benzinga

Analyst Ratings for Intra-Cellular Therapies ↗

March 29, 2023

Via Benzinga

Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features ↗

March 28, 2023

Via Benzinga

Analyst Ratings for Intra-Cellular Therapies ↗

March 02, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023 ↗

April 20, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

April 07, 2023

Via Benzinga

Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

March 29, 2023

Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday.

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Earnings Outlook For Intra-Cellular Therapies ↗

February 28, 2023

Via Benzinga

Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 28, 2023

Gainers

Via Benzinga

Why Intra-Cellular Therapies Climbed Tuesday ↗

March 28, 2023

The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.

Via The Motley Fool

Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted ↗

March 28, 2023

The company believes it may have the answer for patients with "mixed features."

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 28, 2023

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

November 23, 2022

Via Benzinga

Where Intra-Cellular Therapies Stands With Analysts ↗

August 11, 2022

Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings:

Via Benzinga

Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

March 15, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...

Via FinancialNewsMedia

Recap: Intra-Cellular Therapies Q3 Earnings ↗

November 03, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Intra-Cellular Therapies's Earnings: A Preview ↗

November 02, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

September 02, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.08%, resulting in a loss of $86.60...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022 ↗

August 22, 2022

Upgrades

Via Benzinga

Illumina, Poshmark, Olo And Some Other Big Losers From Friday ↗

August 15, 2022

U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Intra-Cellular Therapies: Q2 Earnings Insights ↗

August 09, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.